ArticleTissue engineering. Part A2019
Human Tissue-Engineered Model of Myocardial Ischemia-Reperfusion Injury.
Article in Tissue engineering. Part A, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 57 citations in OpenAlex.
- Heart-on-a-chip and vasculature-on-a-chip platforms as models of cardiovascular disease.Nature reviews. Cardiology · 2026Review
- Epicardial extracellular vesicles modulate gene expression following ischemia-reperfusion injury in heart-on-a-chip.Materials today. Bio · 2026Article
- A Hypoxia-reoxygenation Injury Model in Self-assembling Human Cardioids.Journal of visualized experiments : JoVE · 2026Article
- Humanized hiPSC Platforms for I/R Injury: Advancing Toward Precision Cardioprotection.Cardiovascular therapeutics · 2026Review
- Maturation is required to model ischemia-reperfusion injury in engineered human cardiac tissues.Frontiers in bioengineering and biotechnology · 2026Article
- Review
- Cardiac Ischaemia-Reperfusion Injury: Pathophysiology, Therapeutic Targets and Future Interventions.Biomedicines · 2025Review
- Mitophagy is induced in human engineered heart tissue after simulated ischemia and reperfusion.Journal of cell science · 2025Article
- Hypoxic-Normoxic Crosstalk Activates Pro-Inflammatory Signaling in Human Cardiac Fibroblasts and Myocytes in a Post-Infarct Myocardium on a Chip.Advanced healthcare materials · 2024Article
- Heart-on-a-Chip Model of Epicardial-Myocardial Interaction in Ischemia Reperfusion Injury.Advanced healthcare materials · 2024Article
- Macrophages enhance contractile force in iPSC-derived human engineered cardiac tissue.Cell reports · 2024Article
- Bridging the gap between in vitro and in vivo models: a way forward to clinical translation of mitochondrial transplantation in acute disease states.Stem cell research & therapy · 2024Review
- Advancing Cardiomyocyte Maturation: Current Strategies and Promising Conductive Polymer-Based Approaches.Advanced healthcare materials · 2024Review
- Itaconate and citrate releasing polymer attenuates foreign body response in biofabricated cardiac patches.Materials today. Bio · 2024Article
- Multicellular 3D models to study myocardial ischemia-reperfusion injury.Frontiers in cell and developmental biology · 2024Review
- Cardiac organ chip: advances in construction and application.Biomaterials translational · 2024Review
- Review
- Engineered human cardiac tissues for modeling heart diseases.BMB reports · 2023Review
- Bridging the Translational Gap in Heart Failure Research: Using Human iPSC-derived Cardiomyocytes to Accelerate Therapeutic Insights.Methodist DeBakey cardiovascular journal · 2023Review
- Mechanical response of cardiac microtissues to acute localized injury.American journal of physiology. Heart and circulatory physiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
impact statementReducing ischemia-reperfusion injury would significantly improve patient survival. Current preclinical models are inadequate because they rely on animals, which do not emulate human physiology and the clinical setting. We developed a human tissue platform that allowed us to assess the human cardiac response, and demonstrated the platform's utility by measuring injury during ischemia-reperfusion and the effects of cardioprotective strategies. The model provides a foundation for future studies on how patient-specific backgrounds may affect response to therapeutic strategies. These steps will be necessary to help translate therapies into the clinical setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.